UBS Group’s Virax Biolabs VRAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $561 | Buy |
257
+253
| +6,325% | +$755 | ﹤0.01% | 10568 |
|
|
2026
Q2 | $12 | Buy |
+4
| New | +$17 | ﹤0.01% | 10313 |
|
|
2026
Q1 | – | Sell |
-300
| Closed | -$2.59K | – | 11220 |
|
|
2025
Q4 | $2.59K | Buy |
300
+166
| +124% | +$2.11K | ﹤0.01% | 9276 |
|
|
2025
Q3 | $2.04K | Buy |
+134
| New | +$2.55K | ﹤0.01% | 9232 |
|
|
2025
Q2 | – | Sell |
-897
| Closed | -$25.6K | – | 10873 |
|
|
2025
Q1 | $25.6K | Sell |
897
-620
| -41% | -$27.3K | ﹤0.01% | 8054 |
|
|
2024
Q4 | $85.3K | Buy |
1,517
+696
| +85% | +$33.3K | ﹤0.01% | 6974 |
|
|
2024
Q3 | $39.8K | Buy |
821
+597
| +267% | +$34.3K | ﹤0.01% | 6964 |
|
|
2024
Q2 | $6.5K | Buy |
224
+121
| +117% | +$3K | ﹤0.01% | 7914 |
|
|
2024
Q1 | $1.85K | Buy |
103
+76
| +281% | +$1.77K | ﹤0.01% | 8034 |
|
|
2023
Q4 | $971 | Buy |
27
+26
| +2,600% | +$1.52K | ﹤0.01% | 8454 |
|
|
2023
Q3 | $48 | Buy |
+1
| New | +$94 | ﹤0.01% | 9010 |
|
|
2023
Q2 | – | Sell |
-12
| Closed | -$2.13K | – | 9707 |
|
|
2023
Q1 | $2.13K | Sell |
12
-13
| -52% | -$2.53K | ﹤0.01% | 8570 |
|
|
2022
Q4 | $4.52K | Sell |
25
-24
| -49% | -$8.53K | ﹤0.01% | 9325 |
|
|
2022
Q3 | $38K | Buy |
+49
| New | +$81K | ﹤0.01% | 6619 |
|
Other funds holding VRAX
UBS Group's VRAX Position: Q3 2026 in Review
UBS Group increased its Virax Biolabs (VRAX) stake by 6,325% in Q3 2026, buying an estimated $755 and bringing the position to 257 shares worth $561. The position accounts for ﹤0.01% of the portfolio, ranked #10568.
UBS Group first reported a position in VRAX in Q3 2022 and has held it in 14 quarters since. The position peaked at $85.3K in Q4 2024. 2 funds tracked by Wall St. Rank hold VRAX as of Q3 2026.
- UBS Group held 257 shares of Virax Biolabs worth $561 as of Q3 2026.
- UBS Group bought 253 Virax Biolabs shares in Q3 2026, an estimated $755.
- Virax Biolabs made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10568 holding.
- UBS Group first reported a position in Virax Biolabs in Q3 2022 and has held it in 14 quarters since.
- UBS Group's Virax Biolabs position peaked at $85.3K in Q4 2024.
- 2 funds tracked by Wall St. Rank held Virax Biolabs as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.